



## Final Appraisal Recommendation

Advice No: 2312 – July 2012

### Dexmedetomidine (Dexdor<sup>®</sup>▼) 100 micrograms/ml concentrate for solution for infusion

Submission by: Orion Pharma (UK) Ltd

#### Recommendation of AWMSG

Dexmedetomidine (Dexdor<sup>®</sup>▼) is recommended as an option for use within NHS Wales for the sedation of adult intensive care unit (ICU) patients requiring a sedation level not deeper than arousal in response to verbal stimulation (corresponding to Richmond Agitation-Sedation Scale [RASS] 0 to -3).

#### Additional note:

- AWMSG is of the opinion that dexmedetomidine (Dexdor<sup>®</sup>▼) is appropriate for specialist only prescribing within NHS Wales for the stated indication.

In reaching this recommendation AWMSG took account of the AWMSG Secretariat Assessment Report (ASAR), the preliminary appraisal recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), lay/patient/carer perspective (where available) and discussions at AWMSG.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue:	Orion Pharma (UK) Ltd
Date of first issue	July 2012
Last reviewed	September 2016

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 2312:  
Dexmedetomidine (Dexdor<sup>®</sup>▼) 100 micrograms/ml concentrate for solution for infusion. July 2012



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at [www.evidence.nhs.uk](http://www.evidence.nhs.uk).

For full details on our accreditation visit: [www.nice.org.uk/accreditation](http://www.nice.org.uk/accreditation).